CSPC Pharmaceutical Group Limited (F:CVG) — Market Cap & Net Worth
Market Cap & Net Worth: CSPC Pharmaceutical Group Limited (CVG)
CSPC Pharmaceutical Group Limited (F:CVG) has a market capitalization of $10.18 Billion (€8.71 Billion) as of April 27, 2026. Listed on the F stock exchange, this Germany-based company holds position #2216 globally and #459 in its home market, demonstrating a -2.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CSPC Pharmaceutical Group Limited's stock price €0.97 by its total outstanding shares 11422451732 (11.42 Billion).
CSPC Pharmaceutical Group Limited Market Cap History: 2015 to 2026
CSPC Pharmaceutical Group Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.08 Billion to $12.94 Billion (28.83% CAGR).
CSPC Pharmaceutical Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CSPC Pharmaceutical Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
CSPC Pharmaceutical Group Limited's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.78x
CSPC Pharmaceutical Group Limited's market cap is 1.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.08 Billion | $11.39 Billion | $1.67 Billion | 0.09x | 0.65x |
| 2016 | $1.31 Billion | $11.08 Billion | $1.88 Billion | 0.12x | 0.70x |
| 2017 | $2.45 Billion | $12.92 Billion | $2.32 Billion | 0.19x | 1.06x |
| 2018 | $1.89 Billion | $18.47 Billion | $3.21 Billion | 0.10x | 0.59x |
| 2019 | $3.72 Billion | $22.10 Billion | $3.71 Billion | 0.17x | 1.00x |
| 2020 | $3.25 Billion | $24.94 Billion | $5.16 Billion | 0.13x | 0.63x |
| 2021 | $4.37 Billion | $27.87 Billion | $5.61 Billion | 0.16x | 0.78x |
| 2022 | $5.72 Billion | $30.94 Billion | $6.09 Billion | 0.18x | 0.94x |
| 2023 | $7.04 Billion | $31.45 Billion | $5.87 Billion | 0.22x | 1.20x |
| 2024 | $7.70 Billion | $29.01 Billion | $4.33 Billion | 0.27x | 1.78x |
Competitor Companies of CVG by Market Capitalization
Companies near CSPC Pharmaceutical Group Limited in the global market cap rankings as of April 27, 2026.
Key companies related to CSPC Pharmaceutical Group Limited by market ranking:
- Eli Lilly and Company (SA:LILY34): Ranked #16 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Eli Lilly and Company (NYSE:LLY): Ranked #18 globally with a market cap of $791.16 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #22 globally with a market cap of $548.11 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #39 globally with a market cap of $351.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #18 | Eli Lilly and Company | NYSE:LLY | $791.16 Billion | $883.96 |
| #22 | Johnson & Johnson | NYSE:JNJ | $548.11 Billion | $227.50 |
| #39 | AbbVie Inc | NYSE:ABBV | $351.35 Billion | $198.71 |
CSPC Pharmaceutical Group Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, CSPC Pharmaceutical Group Limited's market cap moved from $1.08 Billion to $ 12.94 Billion, with a yearly change of 28.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.94 Billion | +6.46% |
| 2025 | €12.15 Billion | +57.77% |
| 2024 | €7.70 Billion | +9.37% |
| 2023 | €7.04 Billion | +23.17% |
| 2022 | €5.72 Billion | +30.79% |
| 2021 | €4.37 Billion | +34.35% |
| 2020 | €3.25 Billion | -12.43% |
| 2019 | €3.72 Billion | +96.12% |
| 2018 | €1.89 Billion | -22.54% |
| 2017 | €2.45 Billion | +86.56% |
| 2016 | €1.31 Billion | +21.99% |
| 2015 | €1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 26th, 2026 the market cap of CSPC Pharmaceutical Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.18 Billion USD |
| MoneyControl | $10.18 Billion USD |
| MarketWatch | $10.18 Billion USD |
| marketcap.company | $10.18 Billion USD |
| Reuters | $10.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more